Finanzen von Karyopharm Therapeutics Inc (KPTI)KPTIKaryopharm Therapeutics Inc

Evaluating the bottom line, Karyopharm Therapeutics Inc. maintains a gross margin of 96.75%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -67.38%, while the net margin is -200.48%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively KPTI converts its operational activities into shareholder value.

In the context of the broader market, KPTI competes directly with industry leaders such as ALGS and GRCE. With a market capitalization of $46.72M, it holds a leading position in the sector. When comparing efficiency, KPTI's gross margin of 96.75% stands against ALGS's 100.00% and GRCE's N/A. Such benchmarking helps identify whether Karyopharm Therapeutics Inc. is trading at a premium or discount relative to its financial performance.

Karyopharm's total revenue for Q2 2026 was $33.4 million, down from $37.9 million in Q2 2025, indicating a decline in revenue generation. The gross margin remains high at 96.75%, but the net margin is severely negative at -200.48%, showing ongoing financial distress.